Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais

Detalhes bibliográficos
Autor(a) principal: Schlemmer, Karine Bizzi
Data de Publicação: 2014
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
Texto Completo: http://repositorio.ufsm.br/handle/1/9007
Resumo: The yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis.
id UFSM_856b1467569766a772df779092d4eb9d
oai_identifier_str oai:repositorio.ufsm.br:1/9007
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciaisIn vitro susceptibility of Malassezia pachydermatis against antifungal agents and essential oil fractionsMalassezia pachydermatisSuscetibilidadeIn vitroMalassezia pachydermatisSusceptibilityIn vitroCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAThe yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis.Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorMalassezia pachydermatis é uma levedura pertencente à microbiota normal de animais e, usualmente, apontada como responsável por otites externas e recentemente por diversas formas de dermatites, principalmente em cães. Este estudo teve como objetivo avaliar a suscetibilidade in vitro de 26 isolados de M. pachydermatis frente aos antifúngicos fluconazol, itraconazol, cetoconazol, clotrimazol, miconazol, terbinafina e nistatina, e combinações desses com timol, carvacrol e cinamaldeído, através do método de checkerboard , baseado no documento M27-A3. Também foram avaliadas a atividade do itraconazol, cetoconazol e clotrimazol, em 20 isolados de M. pachydermatis, através da exposição simultânea e sequencial desses agentes utilizando-se a técnica de disco-difusão. Isoladamente, as concentrações inibitórias mínimas (CIMs) para o fluconazol variaram de 1- 64 μg/mL, para o itraconazol 0,01-1 μg/mL, para o cetoconazol 0,01-0,5 μg/mL, para o clotrimazol 0,5-32 μg/mL, para o miconazol 2-32 μg/mL, para a terbinafina 0,12-32 μg/mL e para a nistatina 16-64 μg/mL. Altas taxas de sinergismo foram observadas nas combinações de nistatina + timol (88,46%), nistatina + carvacrol (88,46%), nistatina + cinamaldeído (73,07%), clotrimazol + timol (69,23%), clotrimazol + carvacrol (69,23%), miconazol + timol (65,38%), miconazol + carvacrol (76,92%) e miconazol + cinamaldeído (65,38%). No entanto, fluconazol + timol (53,84%), fluconazol + carvacrol (46,15%), fluconazol + cinamaldeído (65,38%), itraconazol + timol (61,53%), itraconazol + carvacrol (69,23%), itraconazol + cinamaldeído (65,38%), terbinafina + timol (73,07%), terbinafina + carvacrol (65,38%), terbinafina + cinamaldeído (73,07%) e clotrimazol + cinamaldeído (61,53%) tiveram altas taxas de indiferença. Cetoconazol combinado com timol, carvacrol e cinamaldeído apresentaram as maiores taxas de antagonismo (42,3%). A exposição prévia de M. pachydermatis ao itraconazol resultou em uma diminuição da zona de inibição, quando comparado com o itraconazol e cetoconazol usados simultaneamente (p <0,01). Por outro lado, a exposição prévia do clotrimazol aumentou significativamente a zona de inibição (p <0,001), quando comparado à exposição simultânea de clotrimazol e itraconazol. As associações de maior relevância merecem avaliação in vivo, a fim de verificar o potencial das mesmas no tratamento de infecções por M. pachydermatis.Universidade Federal de Santa MariaBRFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaSanturio, Janio Moraishttp://lattes.cnpq.br/6316012260769979Alves, Sydney Hartzhttp://lattes.cnpq.br/0330782478769631Loreto, Érico Silva dehttp://lattes.cnpq.br/5475233864057995Schlemmer, Karine Bizzi2015-03-122015-03-122014-03-14info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfapplication/pdfSCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.http://repositorio.ufsm.br/handle/1/9007porinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-01-28T13:36:43Zoai:repositorio.ufsm.br:1/9007Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2022-01-28T13:36:43Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
In vitro susceptibility of Malassezia pachydermatis against antifungal agents and essential oil fractions
title Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
spellingShingle Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
Schlemmer, Karine Bizzi
Malassezia pachydermatis
Suscetibilidade
In vitro
Malassezia pachydermatis
Susceptibility
In vitro
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
title_full Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
title_fullStr Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
title_full_unstemmed Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
title_sort Suscetibilidade in vitro de Malassezia pachydermatis frente a agentes antifúngicos e frações de óleos essenciais
author Schlemmer, Karine Bizzi
author_facet Schlemmer, Karine Bizzi
author_role author
dc.contributor.none.fl_str_mv Santurio, Janio Morais
http://lattes.cnpq.br/6316012260769979
Alves, Sydney Hartz
http://lattes.cnpq.br/0330782478769631
Loreto, Érico Silva de
http://lattes.cnpq.br/5475233864057995
dc.contributor.author.fl_str_mv Schlemmer, Karine Bizzi
dc.subject.por.fl_str_mv Malassezia pachydermatis
Suscetibilidade
In vitro
Malassezia pachydermatis
Susceptibility
In vitro
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
topic Malassezia pachydermatis
Suscetibilidade
In vitro
Malassezia pachydermatis
Susceptibility
In vitro
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description The yeast Malassezia pachydermatis belongs to the normal microbiota of animals, and is usually implicated as responsible for otitis media and recently by various forms of dermatitis, mainly in dogs. This study aimed to evaluate the in vitro susceptibility of 26 M. pachydermatis isolates against the antifungals fluconazole, itraconazole, ketoconazole, clotrimazole, miconazole, terbinafine and nystatin, and to the combinations of these with thymol, carvacrol and cinnamaldehyde by the checkerboard method, based on document M27-A3. The activity of itraconazol, ketoconazole and clotrimazole against 20 isolates of M. pachydermatis, through simultaneous and sequential exposure of these agents, was also evaluated by the disk-diffusion technique. The minimum inhibitory concentration (MIC) for fluconazole ranged from 1-64 μg/mL, itraconazole 0.01-1 μg/mL, ketoconazole 0.01-0.5 μg/mL, clotrimazole 0.5-32 μg/mL, miconazole 2-32 μg/mL, terbinafine 0.12-32 μg/mL and nystatin 16-64 μg/mL. High rates of synergism were observed in the combinations of nystatin + thymol (88.46%), nystatin + carvacrol (88.46%), nystatin + cinnamaldehyde (73.07%), clotrimazole + thymol (69.23%), clotrimazole + carvacrol (69.23%), miconazole + thymol (65.38%), miconazole + carvacrol (76.92%) and miconazole + cinnamaldehyde (65.38%). However, high rates of indifference were observed in the combinations of fluconazole + thymol (53.84%), carvacrol + fluconazole (46.15%), fluconazole + cinnamaldehyde (65.38%), thymol + itraconazole (61.53%), carvacrol + itraconazole (69.23%), itraconazole + cinnamaldehyde (65.38%), terbinafine + thymol (73.07%), terbinafine + carvacrol (65.38%), terbinafine + cinnamaldehyde (73.07%) and clotrimazole + cinnamaldehyde (61.53%). Ketoconazole combined with thymol, carvacrol and cinnamaldehyde had the highest rates of antagonism (42.3%). The prior exposure of M. pachydermatis to itraconazole resulted in a reduction of the inhibition halo when compared with itraconazole and ketoconazole used simultaneously (p <0.01). Moreover, prior exposure of clotrimazole significantly increased the zone of inhibition (p <0.001) when compared to the simultaneous exposure of itraconazole and clotrimazole. The most significant associations deserve in vivo evaluation in order to verify their potential in the treatment of infections caused by M. pachydermatis.
publishDate 2014
dc.date.none.fl_str_mv 2014-03-14
2015-03-12
2015-03-12
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv SCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.
http://repositorio.ufsm.br/handle/1/9007
identifier_str_mv SCHLEMMER, Karine Bizzi. IN VITRO SUSCEPTIBILITY OF Malassezia pachydermatis AGAINST ANTIFUNGAL AGENTS AND ESSENTIAL OIL FRACTIONS. 2014. 139 f. Dissertação (Mestrado em Farmácia) - Universidade Federal de Santa Maria, Santa Maria, 2014.
url http://repositorio.ufsm.br/handle/1/9007
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
publisher.none.fl_str_mv Universidade Federal de Santa Maria
BR
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1805922084912627712